BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12010622)

  • 21. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
    Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
    Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy.
    Soricelli E; Casella G; Baglio G; Maselli R; Ernesti I; Genco A
    Surg Obes Relat Dis; 2018 Jun; 14(6):751-756. PubMed ID: 29571635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management strategies for gastroesophageal reflux disease.
    Bak YT
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S49-53. PubMed ID: 15324382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!
    Scarpignato C
    Neurogastroenterol Motil; 2012 Aug; 24(8):697-704. PubMed ID: 22783985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic treatment of GERD: Where we are now, and where are we going?
    Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
    Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors in the management of gastroesophageal reflux disease.
    Hrelja N; Zerem E
    Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus.
    Yeh RW; Gerson LB; Triadafilopoulos G
    Dis Esophagus; 2003; 16(3):193-8. PubMed ID: 14641308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton pump inhibitors in pediatrics: evaluation of efficacy in GERD therapy.
    Romano C; Chiaro A; Comito D; Loddo I; Ferrau V
    Curr Clin Pharmacol; 2011 Feb; 6(1):41-7. PubMed ID: 21235462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
    Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
    Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).
    Kalaitzakis E; Björnsson E
    Ther Clin Risk Manag; 2007 Aug; 3(4):653-63. PubMed ID: 18472988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.